Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.
Analysts polled by FactSet expected $0.02.
Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.
Analysts expected $221.1 million.
The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.
Analysts project $999.5 million.
Corcept shares jumped 18% in after-hours trading.